Article Figures & Data
Figures
- Figure 1 MOG-IgG–Positive Pediatric Patients With Clinical Presentation at the First Event and After at Least 24 Months
116/155 MOG-IgG–positive pediatric patients were included in the study. Fifty-nine patients presented with ADEM, 21 patients with unilateral ON, 16 patients with bilateral ON, 6 patients with myelitis, 8 patients with NMOSD, and 6 patients with encephalitis. After at least 24 months of a clinical follow-up, further relapses have occurred in 24 patients with ADEM, 12 patients with unilateral ON, 2 patients with bilateral ON, 1 patient with myelitis, 2 patients with NMOSD, and 3 patients with encephalitis. Thirty-nine/155 patients had to be excluded because of the following reasons: no available serum sample from disease onset (n = 7), insufficient clinical (n = 2) or serologic (n = 26) follow-up data, or a final diagnosis of MS (n = 4). ADEM = acute disseminated encephalomyelitis; IgG = immunoglobulin G; MOG = myelin oligodendrocyte glycoprotein; NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis.
- Figure 2 Comparison of MOG-IgG Titers During Disease Course Between Monophasic and Relapsing Pediatric Patients
Comparison of MOG-IgG titers between monophasic (n = 26) and relapsing (n = 16) pediatric patients in children with serial follow-up in years 1 (months 6–12) and 2 (months 18–24) after onset. MOG-IgG titers show a statistically significant decrease during the first and second years in monophasic patients (A, overall p < 0.001), in contrast to a lower decline during the first and second years in relapsing patients (B, overall p = 0.05). Individual data points in A and B are shown as dots and medians as bars. Groups were statistically compared using the Friedman test and Dunn multiple comparison tests. ***Significant difference to onset at p < 0.001, ns = statistically not significant. IgG = immunoglobulin G; MOG = myelin oligodendrocyte glycoprotein.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
